🇺🇸 FDA
Pipeline program

Xolair 75 mg solution for injection in pre-filled syringe

APHP180614

Approved small_molecule active

Quick answer

Xolair 75 mg solution for injection in pre-filled syringe for Well controlled severe allergic asthma is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Well controlled severe allergic asthma
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials